Denileukin diftitox
From Wikipedia, the free encyclopedia
|
Denileukin diftitox
|
|
| Systematic (IUPAC) name | |
| Diphtheria toxin-Interleukin-2 fusion protein | |
| Identifiers | |
| CAS number | ? |
| ATC code | L01 |
| PubChem | ? |
| DrugBank | |
| Chemical data | |
| Formula | C2560H4042N678O799S17 |
| Mol. mass | 57647.3 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 70-80 min |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
C(US) |
| Legal status | |
| Routes | ? |
Denileukin diftitox, otherwise known as Ontak is an antineoplastic agent, an engineered protein combining Interleukin-2 and Diphtheria toxin. This can bind to Interleukin-2 receptors[1] and introduce the diphtheria toxin into cells that express those receptors, killing the cells. In some Leukemias and Lymphomas malignant cells express these receptors, so denileukin diftitox can target these.
A recent study at the University of Louisville found the drug caused many stage IV malignant melanoma tumors to regress and even stabilize, extending patient life expectancy from about eight months to, as of now, more than a year- which is significant given metastatic malignant melanoma's grave prognosis and poor treatment response.
There is some evidence tying it to vision loss.[2]
[edit] References
- ^ Turturro F (2007). "Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders". Expert Rev Anticancer Ther 7 (1): 11–7. doi:. PMID 17187516.
- ^ Park M, Liu GT, Piltz-Seymour J, et al (2007). "Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy". Leuk. Lymphoma 48 (4): 808–11. doi:. PMID 17454642.
[edit] External links
 |
This protein-related article is a stub. You can help Wikipedia by expanding it. |
